ATRX and pancreatic neuroendocrine tumor: Although the loss of ATRX/DAXX and ALT in pancreatic NET is generally associated with tumor aggressiveness and reduced progression-free survival, these features are associated with better overall survival in the sub-cohort of metastatic patients [15].